Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 10,500 shares, a decrease of 23.9% from the August 31st total of 13,800 shares. Based on an average daily volume of 40,700 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the company's stock are short sold.
Theratechnologies Stock Performance
Shares of Theratechnologies stock traded up $0.06 during trading on Friday, hitting $1.25. 17,055 shares of the stock traded hands, compared to its average volume of 44,874. The stock has a market cap of $57.48 million, a P/E ratio of -6.37 and a beta of 1.41. The company has a fifty day moving average price of $1.33 and a two-hundred day moving average price of $1.34. Theratechnologies has a twelve month low of $0.88 and a twelve month high of $2.58.
Theratechnologies (NASDAQ:THTX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 10th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.04. The business had revenue of $22.02 million for the quarter. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. On average, equities research analysts expect that Theratechnologies will post -0.02 EPS for the current fiscal year.
About Theratechnologies
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
